Bio-Path enters LOI for asset acquisition of DNA programs

Bio-Path Holdings enters a non-binding Letter of Intent with Farrington Capital to potentially acquire or out-license key DNA programs and the DNAbilize platform. This potential asset sale follows the buyer securing a loan facility and offers Bio-Path a path to monetize its biologic and technology portfolio.